MetaCap

Quoin Pharmaceuticals Ltd. ADR (QNRX)

NASDAQ: QNRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.28-0.0791 (-2.35%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QNRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$15.76M
52-week range
3.18 – 23.50
Day range
3.18 – 3.54
Volume / Avg
11.31K / 541.26K
Beta
—

52-week range

$3.18$23.50

QNRX stock today

Quoin Pharmaceuticals (QNRX) closed at $3.28 on Nov 20, down 2.35% (-$0.0791), versus the S&P 500's 3.70% decline. Trading was light, with 11.31K shares changing hands, about 2% of the average daily volume. Shares are 86.0% below their 52-week high of $23.50, set on Nov 25, 2025 and 3.1% above the 52-week low of $3.18, near the bottom of the past year's range.

QNRX is down 77.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.1%. Quoin Pharmaceuticals trades at 7.5x its trailing twelve-month earnings per share of $0.44.

Summary generated from market data by MetaCap's automated system. Methodology

About Quoin Pharmaceuticals

Company profile

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Michael Myers Ph.D.
Headquarters
Ashburn, VA
Employees
4
IPO year
2016

Financial highlights

Full financials

Quoin Pharmaceuticals reported a net loss of $15.8 million, compared with a loss of $9.0 million a year earlier.

Quoin Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue————$0
Growth—————
Net income$-15.80M$-8.96M$-8.69M$-9.38M$-21.46M
EPS (diluted)————$-0.01

Analyst forecast

Forecast

Consensus (5 analysts)

none

Avg. price target

$21.83+565.55%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.97 vs $-1.88
Surprise
+48.40%

QNRX news

All QNRX news

Quoin Pharmaceuticals peers

Health Care sector
QNRX peer companies
CompanyPrice% ChgMarket capCompare
PBMPsyence Biomedical Ltd.2.97+3.85%$15.80Mvs QNRX
ATOSAtossa Therapeutics Inc.1.60-8.86%$15.92Mvs QNRX
LPCNLipocine Inc.1.48-1.33%$16.39Mvs QNRX
CELUCelularity Inc. Class A0.463-1.05%$15.02Mvs QNRX
SHPHShuttle Pharmaceuticals Holdings Inc.3.49-10.51%$16.63Mvs QNRX
AKTXAkari Therapeutics plc ADS7.18+7.00%$16.70Mvs QNRX
CNTXContext Therapeutics Inc.0.16-5.10%$14.70Mvs QNRX
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs QNRX

Indexes, lists and sector

Quoin Pharmaceuticals stock FAQ

What is Quoin Pharmaceuticals's stock price today?

QNRX last traded at $3.28 as of Nov 20, 4:00 PM EST, down 2.35% on the day. Prices are delayed at least 15 minutes.

Does Quoin Pharmaceuticals pay a dividend?

No. Quoin Pharmaceuticals does not currently pay a regular cash dividend.

What is QNRX's P/E ratio?

QNRX trades at a trailing P/E ratio of 7.45.

Who is Quoin Pharmaceuticals's CEO?

Dr. Michael Myers Ph.D. is the chief executive officer of Quoin Pharmaceuticals Ltd. ADR, which has about 4 employees.

Has QNRX ever split its stock?

Yes. The most recent QNRX stock split was a 1-for-35 split on Apr 9, 2025, one of 5 splits on record.

What is the QNRX 52-week high?

The 52-week high for QNRX is $23.50 and the 52-week low is $3.18. The stock is currently 86.0% below its high.

Compare QNRX